吳德燕 男 博士，研究員 博士生導師

電子郵箱：wudeyan@hainanu.edu.cn

辦公地址：365英国上市官网在线（美安）13号樓341-2室

2014年6月博士畢業于華東理工大學365英国上市官网在线，2014年7月-2015年7月工作于上海睿智化學研究有限公司，2015年7月-2021年4月工作于中山大學365英国上市官网在线。2021年4月通過高層次人才引進到365英国上市官网在线工作至今。

1.科研情況

“天然産物導向的創新藥物發現”團隊負責人，主要從事新藥創制、靶向藥物發現的産學研系列工作，團隊通過發展高通量篩選技術與藥物靶标發現技術，搭建基于中藥資源提取物的樣本庫及藥物篩選平台，開展活性成分研究、全合成研究、結構優化及成藥性研究，并在此基礎上開展基于多種疾病模型的藥效研究、作用機制研究及臨床前研究，發現其科學與市場價值。目前已在國内外重要學術刊物J. Med. Chem., Acta Pharm. Sin. B等發表論文30餘篇；發明專利12項；主持國家自然科學基金面上項目、國家自然科學基金青年基金、廣州市科技重點項目、海南省自然科學基金創新研究團隊項目、海南省自然科學基金高層次人才項目等項目9項，科研經費超過500萬元。

2.研究領域

天然産物導向的創新藥物發現

藥物分子設計、結構優化及作用機制研究

活性天然産物全合成、結構修飾及成藥性研究

3.代表性科研項目

1) 國家自然科學基金面上項目，高選擇性PDE5抑制劑的合理設計、結構優化及其抗肺纖維化作用研究，2024.01-2027.12，主持

2)國家自然科學基金面上項目，吡咯色原酮類PDE5特異性抑制劑的設計、抗肺動脈高壓活性及作用機制研究，2019.01-2022.12，主持

3)國家自然科學基金青年基金項目，抗慢性阻塞性肺病PDE4高選擇性抑制劑的發現:天然産物桑辛素M的結構優化及生物活性研究，2017.01-2019.12，主持

4)廣州市科技重點項目，抗肺動脈高壓I類創新化學藥（PDE5抑制劑羅達那非）的臨床前研究，2018.04-2021.03，主持

5)海南省自然科學基金創新研究團隊項目，抗肺纖維化創新藥物發現，2023.03-2026.02，主持

6)海南省自然科學基金高層次人才項目，磷酸二酯酶四型（PDE4）選擇性抑制劑的合理設計與結構優化，2022.04-2025.03，主持

4.代表性論文

1) Sen Wang^#, Guofeng Yang^#, Kai Zhang, Zhexin Chen, Meiying Qiu, Siyu Hou, Tiansheng Zheng, Zongmin Wu, Qinjiang Ma, Furong Zhang, Ge Gao, Yi-You Huang, Qian Zhou*, Hai-Bin Luo*, Deyan Wu*. Structural optimization of Moracin M as novel selective phosphodiesterase 4 inhibitors for the treatment of idiopathic pulmonary fibrosis. Bioorg. Chem. 2024, 149, 107474.

2) Deyan Wu^#, Xuehua Zheng^#, Runduo Liu, Zhe Li, Zan Jiang, Qian Zhou, Yue Huang, Xu-Nian Wu, Chen Zhang, Yi-You Huang^*, Hai-Bin Luo^*. Free Energy Perturbation (FEP)-Guided Scaffold Hopping. Acta Pharm. Sin. B 2022, 12, 1351-1362.

3) Meiying Qiu^#, Deyan Wu^#, Yi-You Huang, Yue Huang, Qian Zhou, Yijing Tian, Lei Guo, Yuqi Gao*, Hai-Bin Luo*. Discovery of catalytic-site-fluorescent probes for tracing phosphodiesterase 5 in living cells. RSC Adv. 2021, 11, 31967.

4) Yi-You Huang^#, Yan-Fa Yu^#, Chen Zhang^#, Yiping Chen, Qian Zhou, Zhuoming Li, Sihang Zhou, Zhe Li, Lei Guo, Deyan Wu*, Yinuo Wu*, Hai-Bin Luo*. Validation of Phosphodiesterase-10 as a Novel Target for Pulmonary Arterial Hypertension via Highly Selective and Subnanomolar Inhibitors. J. Med. Chem. 2019, 62, 3707-3721.

5) Deyan Wu^#, Yadan Huang^#, Yiping Chen^#, Yi-You Huang, Haiju Geng, Tianhua Zhang, Chen Zhang, Zhe Li, Lei Guo, Jianwen Chen, and Hai-Bin Luo*. Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Highly Potent, Selective, and Orally Bioavailable PDE5 Inhibitors: Structure–Activity Relationship, X-ray Crystal Structure, and Pharmacodynamic Effect on Pulmonary Arterial Hypertension. J. Med. Chem. 2018, 61, 8468-8473. 封面論文

6) Deyan Wu^#, Tianhua Zhang^#, Yiping Chen, Yadan Huang, Haiju Geng, Yanfa Yu, Chen Zhang, Zengwei Lai, Yinuo Wu, Xiaolei Guo, Jianwen Chen,* Hai-Bin Luo*. Discovery and Optimization of Chromeno[2,3-c]pyrrol-9(2H)-ones as Novel Selective and Orally Bioavailable Phosphodiesterase 5 Inhibitors for the Treatment of Pulmonary Arterial Hypertension.. J. Med. Chem. 2017, 60, 6622-6637. 封面論文

7) Yan-Fa Yu^#, Chen Zhang^#, Yi-You Huang^#, Sirui Zhang, Qian Zhou, Xiangmin Li, Zengwei Lai, Zhe Li, Yuqi Gao, Yinuo Wu, Lei Guo*, Deyan Wu*, Hai-Bin Luo. Discovery and Optimization of Chromone Derivatives as Novel Selective Phosphodiesterase 10 Inhibitors. ACS Chem. Neurosci. 2020, 11, 1058-1071.

8) Jinxuan Li^#, Jing-Yi Chen^#, Ya-Lin Deng, Qian Zhou, Yinuo Wu*, Deyan Wu*, Hai-Bin Luo. Structure-Based Design, Synthesis, Biological Evaluation, and Molecular Docking of Novel PDE10 Inhibitors With Antioxidant Activities. Front. Chem. 2018, 6, 167.

9) Yinuo Wu, Zhe Li, Yi-You Huang, Deyan Wu, Hai-Bin Luo*. Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer’s Disease. J. Med. Chem. 2018, 61, 5467-5483.

10) Zhe Li^#, Xin Li^#, Yi-You Huang^#, Yaoxing Wu^#, Runduo Liu, Lingli Zhou, Yuxi Lin, Deyan Wu, Lei Zhang, Hao Liu, Ximing Xu, Kunqian Yu, Yuxia Zhang, Jun Cui*, Chang-Guo Zhan*, Xin Wang*, Hai-Bin Luo*. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. PNAS 2020, 117, 27381-27387.

11) Senling Feng^#, Huifang Zhou^#, Deyan Wu, Dechong Zheng, Biao Qu, Ruiming Liu, Chen Zhang, Zhe Li, Ying Xie*, Hai-Bin Luo*. Nobiletin and its derivatives overcome multidrug resistance (MDR) in cancer: total synthesis and discovery of potent MDR reversal agents, Acta Pharm. Sin. B 2020, 10, 327-343.

12) Lu Liu, Deyan Wu, Shu Zheng, Tengfei Li, Xiangmin Li, Sinan Wang, Jian Li, Hao Li*, Wei Wang*. Synthesis of Highly Functionalized Chiral 3,3′-Disubstituted Oxindoles via an Organocatalytic Enantioselective Michael Addition of Nitroalkanes to Indolylidenecyanoacetates. Organic Lett. 2012, 14, 134-137.